News | News By Subject | News by Disease News By Date | Search News

Testosterone replacement News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Repros Therapeutics (RPRX) to Ditch Efforts to Seek Approval of Testosterone Drug in the U.S. if Key Study Fails     4/15/2016
Embattled Acerus (TRLPF) Loses U.S. Distribution Deal for Natesto With Endo International (ENDP)     12/31/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Lipocine Inc. (LPCN) Testosterone Therapy Meets Phase 3 Goals     9/24/2014
FDA Panel Denies Clarus Therapeutics' Oral Testosterone Drug Rextoro     9/19/2014
AbbVie (ABBV), Teva Pharmaceutical Industries Limited (TEVA) Illegally Blocked Generic Version Of AndroGel: Federal Trade Commission     9/9/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study     8/28/2014
25 Medical Societies Petition JAMA To Retract Misleading Testosterone Study     4/10/2014
Clarus Therapeutics Touts Phase 3 Success for Oral Testosterone Replacement Therapy     9/25/2012
BioSante Pharmaceuticals, Inc. (BPAX), Teva Pharmaceutical Industries Limited (TEVA) Surge as FDA OKs Testosterone Gel     2/16/2012
FDA Seeks Another Trial On Repros Therapeutics Inc. (RPRX) Testosterone Drug, Androxal     11/10/2010
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment     9/3/2009
Watson Pharmaceuticals, Inc. (WPI) Receives FDA Approval For Testosterone Gel Product     1/30/2006
P&G Pharmaceuticals, Inc. (PG) Release: Landmark Clinical Study Shows Female Testosterone Patch Significantly Improved Sexual Desire In Surgically Menopausal Women     5/4/2004

News from Around the Web

Press Releases
Lipocine (LPCN) To Initiate Dosing Validation Study For LPCN 1021, Oral Testosterone Replacement Product Candidate     12/5/2016
Lipocine (LPCN) Completes Post Action Meeting With FDA For LPCN 1021 New Drug Application     10/17/2016
Clarus Therapeutics Provides Update On Patent Infringement Lawsuit Against Lipocine (LPCN)'s Oral Product For Testosterone Replacement Therapy     10/13/2016
Repros Therapeutics (RPRX) Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities     10/6/2016
Lipocine (LPCN) Announces Positive Top-Line Phase IIb Study Results For LPCN 1111, A Next Generation Oral Testosterone Replacement Therapy     9/26/2016
Embattled Acerus (TRLPF) Loses U.S. Distribution Deal for Natesto With Endo International (ENDP)     12/31/2015
Clarus Therapeutics Seeks Injunction Against The Marketing Of Lipocine Inc. (LPCN)'s Oral Product For Testosterone Replacement Therapy (LPCN 1021)     11/3/2015
Lipocine Inc. (LPCN) Submits New Drug Application To FDA For Its Oral Testosterone Replacement Product Candidate, LPCN 1021     8/31/2015
Trimel Pharmaceuticals (TRL.TO) Announces Second Quarter 2015 Financial Results And Highlights     8/5/2015
Lipocine Inc. (LPCN)'s Oral Testosterone Well Tolerated In Phase III Study     6/30/2015
Lipocine Inc. (LPCN) Announces Successful Completion Of Food Effect Study For LPCN 1021, An Oral Testosterone Product Candidate     6/15/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Urological Association Annual Meeting     5/11/2015
Lipocine Inc. (LPCN) Announces Completion Of LPCN 1021, Oral Testosterone, Phase III Clinical Trial     4/30/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Society Of Andrology 40th Annual Conference     4/10/2015
Lipocine Inc. (LPCN) Announces Results From Pre-NDA Meeting For LPCN 1021, An Oral Testosterone Product Candidate     3/24/2015

//-->